64th ASH Annual Meeting and Exposition: 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Genomic Markers of Disease Progression and Therapeutic Response

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Research, Biological therapies, Fundamental Science, adult, Translational Research, assays, genomics, bioinformatics, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Diseases, Gene Therapy, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, Study Population, Human, pathogenesis, omics technologies

New Orleans Theater AB (Ernest N. Morial Convention Center)

Moderators:

Raphael E Szalat, MD, PhD, Boston University School of Medicine and Niccolo Bolli, MD, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico & University of Milan

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

642

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Eugenio Morelli, MD¹, Annamaria Gulla, MD², Na Liu³^*, Domenico Maisano, PhD⁴^*, Anil Aktas-Samur, PhD⁵^*, Nicola Amodio, PhD⁶^*, Caroline Ribeiro, PhD⁷^*, Leon Wert-Lamas, PhD³^*, Jonathan Henninger⁸^*, Srikanth Talluri, PhD⁹^*, Megan Johnstone¹⁰^*, Doriana Gramegna¹^*, Delaney Vinaixa¹¹^*, Antonino Neri, MD¹², Dharminder Chauhan, PhD¹³^*, Teru Hideshima, MD, PhD¹, Masood A. Shammas, PhD¹⁴^*, Pierfrancesco Tassone, MD¹⁵^*, Sergei Gryaznov¹⁶^*, Richard A. Young, PhD¹⁷^*, Kenneth C. Anderson, MD⁹, Carl D. Novina, MD, PhD⁹, Massimo Loda, MD¹⁸^*, Mariateresa Fulciniti, PhD⁹, Mehmet K. Samur, PhD⁹ and Nikhil C Munshi, MD, PhD¹⁹

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
²Medical Oncology, Dana Farber Cancer Institute, Boston, MA
³Dana-Farber Cancer Institute, Boston
⁴Dana Farber Cancer Institute, Boston, MA
⁵Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁶Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
⁷Cornell University, new york
⁸Whitehead Institute of Biomedical Research, Cambridge, MA
⁹Dana-Farber Cancer Institute, Boston, MA
¹⁰Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹¹Medical Oncology, Dana-Farber Cancer Institute, Boston
¹²BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy
¹³Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁴The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston
¹⁵Magna Graecia University, Catanzaro, Italy
¹⁶Maia Biotechnology Inc., CHICAGO, IL
¹⁷Whitehead Institute For Biomedical Research/ MIT, Cambridge, MA
¹⁸Weill Cornell Medical College, New York, NY
¹⁹Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

4:45 PM

638

Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma

Monika Chojnacka, BS¹, Benjamin Diamond²^*, Bachisio Ziccheddu, PhD³^*, Even Rustad⁴^*, Eileen Boyle⁵^*, Kylee H Maclachlan, MBBCh, PhD⁶, Patrick Blaney⁷^*, Saad Usmani, MD⁷, Gareth J. Morgan, MD⁵, Ola Landgren, MD² and Francesco Maura, MD⁸

¹Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami
²Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami
³Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
⁴Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
⁵Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York
⁶Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
⁸Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, PALMETTO BAY, FL

5:00 PM

639

Intergenic Non-Switch Immunoglobulin Translocations Are Frequently Observed in Genomically Unstable MM

Mehmet K. Samur, PhD¹, Jill Corre²^*, Luka Pavageau³^*, Laure Buisson⁴^*, Nikhil C Munshi, MD, PhD⁵ and Herve Avet-Loiseau, MD, PhD⁶^*

¹Dana-Farber Cancer Institute, Boston, MA
²Toulouse, and CRCT, Toulouse, France, Toulouse, France
³Iuct-Oncopole, Toulouse, FRA
⁴Iuct-Oncopole, TOULOUSE, FRA
⁵Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
⁶Unit for Genomics in Myeloma, Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, France

5:15 PM

640

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Hitomi Hosoya, MD, PhD¹, Mia Carleton²^*, Kailee L Tanaka²^*, Brian Sworder, MD, PhD³, Vanna Hovanky⁴^*, George E Duran, BA²^*, Tian Y. Zhang⁵, Michael S. Khodadoust, MD PhD², David B. Miklos, MD, PhD⁴, Sally Arai, MD⁶, David Iberri, MD², Michaela Liedtke, MD², Surbhi Sidana, MD⁷ and David M. Kurtz, MD, PhD¹

¹Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
²Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
³Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
⁴Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
⁵Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA
⁶Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University Medical Center, Stanford, CA
⁷Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA

5:30 PM

641

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia

Maria Luisa Guerrera, MD¹^*, Xia Liu, MD¹^*, Eugenio Morelli, MD², Kris Richardson, PhD¹^*, Nickolas Tsakmaklis¹^*, Amanda Kofides¹^*, Manit Munshi, MS¹^*, Shirong Liu, MD PhD¹^*, Guang Yang, PhD¹, Christopher J Patterson, MS, MPH¹^*, Jorge J. Castillo, MD¹, Shayna Sarosiek, MD¹, Catherine A. Flynn, NP¹^*, Kirsten Meid, MPH¹^*, Joshua Gustine, MPH¹^*, Andrew R. Branagan, MD³, Alessandra Trojani, PhD⁴^*, Alessandra Tedeschi⁴^*, Roberto Cairoli⁴^*, Tomasz Sewastianik, PhD⁵^*, Ruben D. Carrasco, MD, PhD⁵^*, Kenneth C. Anderson, MD², Nikhil C Munshi, MD, PhD², Steven P Treon, MD, PhD¹ and Zachary R Hunter, PhD¹

¹Bing Center for Waldenstrom's macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA
²Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
³Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
⁴Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
⁵Department of Pathology, Dana-Farber Cancer Institute, Boston, MA

5:45 PM

637

Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma

Francesco Maura, MD¹, David Coffey, MD¹, Esteban Braggio, PhD², Caleb K Stein, PhD³^*, Meaghen E Sharik, BS³^*, Megan T Du, B.S.³^*, Bachisio Ziccheddu, PhD¹^*, Gareth J. Morgan, MD⁴, Ola Landgren, MD⁵, P. Leif Bergsagel, MD⁶ and Marta Chesi, PhD⁶

¹Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami
²Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
³Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale
⁴NYU Langone, Perlmutter Cancer Center, New York
⁵Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
⁶Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651A.O2.6 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Genomic Markers of Disease Progression and Therapeutic Response